Skip to content


Nina Herne

Nina Herne

CEO since 2021

Born: 1969

Education: Ph.D. in Immunology from Lund University and an Executive MBA from Stockholm School of Economics as well as board member education via Styrelseinstitutet and Stockholm School of Economics

Work experience: Several senior positions in global pharmaceutical companies, most recently at Chiesi Group. Extensive experience from R&D, operations, business development and licensing, strategy development and international stakeholder management from smaller organizations like Zymenex (Managing Director for Sweden and Denmark) and NeuroNova, as well as larger companies like Chiesi, SOBI and NovoZymes (NovoNordisk).

Holdings: 0 shares, 100 000 warrants


Jenni Björnulfson

CFO and Head of IR since 2021

Born: 1971

Education: Master’s degree in Finance and Managerial economics from Stockholm School of Economics and studies at the Karolinska Institute

Other Assignments: Board director in Hemcheck Sweden AB (publ), listed on Nasdaq First North Growth Market

Work experience: Extensive financial and industrial background working for many years within the health care sector. Previous positions include being CFO for Promore Pharma and Cinclus Pharma Holding. Prior to that Jenni worked as an equities analyst at ABG Sundal Collier and she has held corporate finance positions at Alfred Berg and Handelsbanken

Holdings: 0 shares, 35,000 warrants

Matthew Lindon

CSO since 2022

Born: 1973

Education: Bachelor of Science in Chemistry from the University of Leicester

Work experience: Strong background from the pharmaceutical sector with over 20 years’ experience of integrated drug discovery and development. Previous positions include Senior Director and Global Project Leader with a focus on drug discovery and early clinical development at GSK, and most recently at AstraZeneca where he was leading a portfolio of drug discovery and development projects in the Respiratory & Immunology therapy area.

Holdings: 0 shares, 0 warrants